Home›Trial›NCT06925685
NCT06925685ENROLLING BY INVITATION

Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product

Study Summary

An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study. Participants will be followed for 15 years after their last infusion of an allogenic CAR T cell product.

Conditions
Hematologic MalignanciesSolid Tumors
Interventions / Drugs
View on ClinicalTrials.gov ↗
Sponsor
ALLO
Allogene Therapeutics
Cell Therapy
A81/100
Study Details
Enrollment50 participants
Primary Completion—
Lead SponsorAllogene Therapeutics
Data Retrieved2026-04-11 02:53:23.197992+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 50 participants
Sponsor Catalyst Profile

Allogene Therapeutics (ALLO) is the sponsoring company for this trial. BiotechSign currently grades this company A (81/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ALLO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.